Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians. - Wikidata - awgldk - TriplyDB

Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.

Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.

http://www.wikidata.org/entity/Q44579110

about

Systematic review and meta-analysis of linezolid versus daptomycin for treatment of vancomycin-resistant enterococcal bacteremia In vitro activity of daptomycin against Enterococcus faecalis under various conditions of growth-phases, inoculum and pH Antimicrobial resistance status of Enterococcus from Australian cattle populations at slaughter.Genetic basis for daptomycin resistance in enterococci.Identification of a novel clone, ST736, among Enterococcus faecium clinical isolates and its association with daptomycin nonsusceptibility.Decolonization of gastrointestinal carriage of vancomycin-resistant Enterococcus faecium: case series and review of literature.Treatment considerations in vancomycin-resistant enterococcal bacteremia: daptomycin or linezolid? A review.Comparative analysis of the complete genome of an epidemic hospital sequence type 203 clone of vancomycin-resistant Enterococcus faecium Enterococcal endocarditis: can we win the war?Ampicillin enhances daptomycin- and cationic host defense peptide-mediated killing of ampicillin- and vancomycin-resistant Enterococcus faecium.In vitro activity of daptomycin in combination with β-lactams, gentamicin, rifampin, and tigecycline against daptomycin-nonsusceptible enterococci.De novo daptomycin-nonsusceptible enterococcal infections.Comparison of the Effectiveness and Safety of Linezolid and Daptomycin in Vancomycin-Resistant Enterococcal Bloodstream Infection: A National Cohort Study of Veterans Affairs Patients Trends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline, daptomycin, and linezolid and molecular epidemiology of the isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006 to 2010 Differential Effects of Penicillin Binding Protein Deletion on the Susceptibility of Enterococcus faecium to Cationic Peptide Antibiotics Daptomycin exposure precedes infection and/or colonization with daptomycin non-susceptible enterococcus.Intrinsic and acquired resistance mechanisms in enterococcus.Genetic modifications to temperate Enterococcus faecalis phage Ef11 that abolish the establishment of lysogeny and sensitivity to repressor, and increase host range and productivity of lytic infection.Multicenter study of high-dose daptomycin for treatment of enterococcal infections A current perspective on daptomycin for the clinical microbiologist.Daptomycin-Vancomycin-Resistant Enterococcus faecium Native Valve Endocarditis: Successfully Treated With Off-Label Quinupristin-Dalfopristin.Frequency of susceptibility testing for patients with persistent methicillin-resistant Staphylococcus aureus bacteremia.Current and prospective treatments for multidrug-resistant gram-positive infections.The zoonotic potential of daptomycin non-susceptible enterococci.Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.Vancomycin-resistant enterococcal bacteremia pharmacotherapy.Ceftaroline restores daptomycin activity against daptomycin-nonsusceptible vancomycin-resistant Enterococcus faecium.Therapeutic options for vancomycin-resistant enterococcal bacteremia.Enterococcal endocarditis revisited.Multidrug-resistant Enterobacteriaceae, Pseudomonas aeruginosa, and vancomycin-resistant enterococci: Three major threats to hematopoietic stem cell transplant recipients.Daptomycin nonsusceptible vancomycin resistant Enterococcus bloodstream infections in patients with hematological malignancies: risk factors and outcomes.Phenylthiazole Antibacterial Agents Targeting Cell Wall Synthesis Exhibit Potent Activity in Vitro and in Vivo against Vancomycin-Resistant Enterococci.Early in vitro development of daptomycin non-susceptibility in high-level aminoglycoside-resistant Enterococcus faecalis predicts the efficacy of the combination of high-dose daptomycin plus ampicillin in an in vivo model of experimental endocarditi Vancomycin-resistant enterococci with reduced daptomycin susceptibility in Singapore: prevalence and associated factors.Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.Characterization of daptomycin non-susceptible Enterococcus faecium producing urinary tract infection in a renal transplant recipient.What's New in the Treatment of Enterococcal Endocarditis?Genotypic and phenotypic evaluation of the evolution of high-level daptomycin nonsusceptibility in vancomycin-resistant Enterococcus faecium.False daptomycin-nonsusceptible MIC results by Microscan panel PC 29 relative to Etest results for Staphylococcus aureus and enterococci.Performance of Vitek 2 for antimicrobial susceptibility testing of Staphylococcus spp. and Enterococcus spp.

P2860

Q28302184-A01CA742-FED6-4876-8527-575FCF0E61BB Q28488311-DFB9268C-BD7B-45A3-9232-A6C6AFD8B74C Q33703920-CA385C77-883F-4E00-8977-8282D3BE737C Q33876255-95372253-5EFB-4F7C-AC18-E21A25C062FC Q34058360-4FA47B71-9EC7-433E-9270-9BEECC161DD0 Q34271283-124225DC-1DC0-47D3-8B67-FBFC6F6412D0 Q34871254-FC5E36B1-C01B-4E04-8C8D-CEB17F9484ED Q34978334-40C54D62-35B3-4295-9933-D79E86386250 Q35610638-7774A707-12F6-4619-AAEA-4940B8FC0D5B Q35689222-11269076-EA9F-461F-9558-AADA3EB0CE0A Q35746209-21740D97-27C3-432A-9D72-7CBD3125F198 Q35844661-43929048-13E5-492A-B2B9-91CFA9848353 Q35999714-C155A655-6CC1-448C-B382-2AF52F71D291 Q36018925-4BD7131A-24F1-47A5-8AD6-58C2379A9B07 Q36075839-C846B1CC-4280-4B55-AEAF-513DCAB523BB Q36217683-6D0BF36F-D248-4F2B-B988-5E52A0AB30B1 Q36362547-B712AA2E-B529-45BD-A9E9-3FB2D170C2A4 Q37007036-1B949B76-3782-42E3-B8EB-B31E7A923C68 Q37124177-0EA5F003-5ECA-4F4F-891B-3D1D99A22D20 Q37263289-3C9FEB55-3EE2-4432-9117-68610989D82A Q37265349-AA6D0815-B1C4-4339-8065-9617C5205E52 Q37546815-BDFABF0E-9AB3-4829-A65E-E85B43878B98 Q38123255-39FBEAB5-F8BE-406E-923E-F4BBE394B2C0 Q38166035-1668FBA7-5410-4317-A67C-BA2A684E6151 Q38255366-8888BD96-8960-43F8-982A-1BBB11A0A177 Q38263421-D4AE52F2-BA7B-4ABF-BED8-D1BDD04048DF Q38325502-7419235A-8ACF-42F3-BA66-DB5533BDB8B4 Q38347869-A020CFD2-467C-4945-84EA-7A4FC5A9D973 Q38539279-BCF00769-9427-4D64-B5DD-A32C791BDDE9 Q38620812-ED5FFC69-4352-4703-AB95-1554420EDA0E Q40254524-CB9F3540-B082-496A-A784-E79BEF61688D Q40313144-53E8360C-727B-422B-86E5-88A2E4EED330 Q40330828-AEA74E5B-0F04-452E-9006-129A7110B078 Q40676263-7F051FEF-BBA8-4EC2-910C-21C3BBC9E21F Q40947815-E282278F-607F-48F7-BA32-6E6083962DB9 Q41096202-C1F0B690-5254-40A0-B60A-3D8D097E4835 Q41368979-166E7A31-7624-4204-ACB9-F503E8D38752 Q41570641-86910EBE-8ED3-4DC6-B725-7D1E08471040 Q41838887-0D09DFCF-5FA6-4137-BAB1-CF92B6AC6F76 Q41908540-E0B7669C-DC8C-42D2-9C82-E021BF86C8D4

P2860

Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.

http://www.wikidata.org/entity/Q44579110

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年学术文章

@wuu

2011年学术文章

@zh

2011年学术文章

@zh-cn

2011年学术文章

@zh-hans

2011年学术文章

@zh-my

2011年学术文章

@zh-sg

2011年學術文章

@yue

2011年學術文章

@zh-hant

name

Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.

@en

Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.

@nl

type

label

Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.

@en

Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.

@nl

prefLabel

Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.

@en

Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.

@nl

P1433

Q44579110-BF2EF2BC-79C7-47C8-B159-3C76C9F7F015

P1476

Q44579110-CCFED488-2318-4ABE-B063-D1B46EA38B4B

P2093

Q44579110-A8C8A65E-ACF6-48A2-8595-46064B0C46DE

Q44579110-B43103EB-1BFF-4D85-82E8-0A4D06AEEF5C

Q44579110-EE5BEFD6-1701-4B1A-BC19-CFB058D56F3F

P2860

Q44579110-027A269B-EBB2-42E1-BD10-995CF123401F

Q44579110-0391769D-6579-4C98-81C8-02D35683EFB0

Q44579110-04EA38FC-2B69-474F-B461-821B83275EFC

Q44579110-15CE3CCB-4288-48D8-96A5-E7867C590EBF

Q44579110-1AB7C9BE-D2EC-4049-9052-101BC2BCA948

Q44579110-1B38BD53-2110-4534-997E-CA497B0A448E

Q44579110-20C969EE-5F0B-438D-BDCE-DF5450FA4960

Q44579110-24BD29CC-BCD8-45C2-902B-74FDFC885942

Q44579110-25A810A6-282B-4E87-9C28-50E3EFCA67CE

Q44579110-2B4E3770-206D-4B86-9FEA-6AD3AB9EBB21

P304

Q44579110-B6053FAB-F417-455F-B37E-87548940DB51

P31

Q44579110-5C5B10D4-E96F-42C6-A4C8-BFBB4878EC6E

P356

Q44579110-1AAF6FD5-D6BA-44F0-AEB1-6BBF5F7F5EA9

P407

Q44579110-B6BDD09C-9AEC-4BBF-9D1A-0157482C80B7

P433

Q44579110-9246AB31-B3B0-42E5-8F52-260ED341231B

P478

Q44579110-41937B2C-3CC6-4419-AD30-7B3F2CDFD7D7

P50

Q44579110-5787F463-FDE2-4909-8067-28E59CAEE821

P577

Q44579110-FDF692EC-C98D-48B5-B3A2-29E7781835B4

P5875

Q44579110-40878E3E-59D4-4C63-90B5-53DC86EFBDBC

P698

Q44579110-6E4F100A-F369-4112-9E82-8890FE2925C9

P356

P1433

Clinical Infectious Diseases

P1476

Daptomycin nonsusceptible enterococci: an emerging challenge for clinicians.

@en

P2093

Daniel Z Uslan

http://www.w3.org/2001/XMLSchema#string

David A Pegues

http://www.w3.org/2001/XMLSchema#string

Romney Humphries

http://www.w3.org/2001/XMLSchema#string

P2860

Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vi

Resistance studies with daptomycin

Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus.

Baseline study to determine in vitro activities of daptomycin against gram-positive pathogens isolated in the United States in 2000-2001

Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers

Daptomycin (LY146032) treatment of experimental enterococcal endocarditis

Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens.

Mechanisms of resistance to daptomycin in Enterococcus faecium.

In vitro activity of daptomycin against clinical isolates with reduced susceptibilities to linezolid and quinupristin/dalfopristin.

P304

228-234

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/CID/CIQ113

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

52

http://www.w3.org/2001/XMLSchema#string

P50

Theodoros Kelesidis

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

49805498

http://www.w3.org/2001/XMLSchema#string

P698

21288849

http://www.w3.org/2001/XMLSchema#string